公开(公告)号：US20180258491A1

公开(公告)日：2018-09-13

申请号：US15853699

申请日：2017-12-22

Applicant: Zainab JAGANI ,  Gregory HOFFMAN ,  Frank Peter STEGMEIER ,  Craig Stephen MICKANIN

Inventor： Zainab JAGANI ,  Gregory HOFFMAN ,  Frank Peter STEGMEIER ,  Craig Stephen MICKANIN

IPC: C12Q1/6886 ,  C12N15/113 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/30 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/57496 ,  G01N2333/914

Abstract: The invention provides methods of detecting cancer biomarkers, such as one or more SWI/SNF complex mutations, in order to determine a cancer subject's amenability to therapeutic treatment with a BRM inhibitor. Kits, methods of screening for candidate FIRM inhibitors, and associated methods of treatment are also provided.

公开(公告)号：US06833241B2

公开(公告)日：2004-12-21

申请号：US09813492

申请日：2001-03-21

Applicant: Mark A. Labow ,  Craig Stephen Mickanin ,  Umesh Bhatia

Inventor： Mark A. Labow ,  Craig Stephen Mickanin ,  Umesh Bhatia

IPC: G01N3348

CPC classification number: A61K38/195 ,  C12Q1/6886 ,  C12Q2600/136 ,  G01N33/57484 ,  G01N33/6863

Abstract: The present invention provides various methods for utilizing a polypeptide encoding a chemokine (MEC) and a polypeptide translated therefrom. The MEC chemokine is underexpressed in tumors, making the chemokine a useful marker for diagnosis and prognosis of adverse bodily reactions.

Abstract translation: 本发明提供了利用编码趋化因子（MEC）的多肽和从其翻译的多肽的各种方法。 MEC趋化因子在肿瘤中表达较低，使趋化因子成为诊断和不良身体反应预后的有用标志物。

公开(公告)号：US09850543B2

公开(公告)日：2017-12-26

申请号：US14777211

申请日：2014-03-12

Applicant: Zainab Jagani ,  Gregory Hoffman ,  Frank Peter Stegmeier ,  Craig Stephen Mickanin

Inventor： Zainab Jagani ,  Gregory Hoffman ,  Frank Peter Stegmeier ,  Craig Stephen Mickanin

IPC: A61K31/70 ,  C07H21/02 ,  C07H21/04 ,  C12Q1/68 ,  C12N15/113 ,  G01N33/574 ,  C12N5/00

CPC classification number: C12Q1/6886 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/30 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/57496 ,  G01N2333/914

Abstract: The invention provides methods of detecting cancer biomarkers, such as one or more SWI/SNF complex mutations, in order to determine a cancer subject's amenability to therapeutic treatment with a BRM inhibitor. Kits, methods of screening for candidate BRM inhibitors, and associated methods of treatment are also provided.

公开(公告)号：US20160032402A1

公开(公告)日：2016-02-04

申请号：US14777211

申请日：2014-03-12

Applicant: Zainab JAGANI ,  Gregory HOFFMAN ,  Frank Peter STEGMEIER ,  Craig Stephen MICKANIN

Inventor： Zainab JAGANI ,  Gregory HOFFMAN ,  Frank Peter STEGMEIER ,  Craig Stephen MICKANIN

IPC: C12Q1/68 ,  G01N33/574 ,  C12N15/113

CPC classification number: C12Q1/6886 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/30 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/57496 ,  G01N2333/914

Abstract: The invention provides methods of detecting cancer biomarkers, such as one or more SWI/SNF complex mutations, in order to determine a cancer subject's amenability to therapeutic treatment with a BRM inhibitor. Kits, methods of screening for candidate BRM inhibitors, and associated methods of treatment are also provided.

Abstract translation: 本发明提供了检测癌症生物标志物（例如一种或多种SWI / SNF复合体突变）的方法，以便确定癌症受试者对BRM抑制剂的治疗性治疗的适应性。 还提供了试剂盒，筛选候选BRM抑制剂的方法和相关的治疗方法。